|
|
Volumn 14, Issue 1, 2008, Pages 65-69
|
|
Cost-effective pharmacologic therapies to treat chronic hepatitis B: How far have we really come?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADEFOVIR DIPIVOXIL;
ALPHA2B INTERFERON;
ANTIVIRUS AGENT;
ENTECAVIR;
HEPATITIS B(E) ANTIBODY;
HEPATITIS B(E) ANTIGEN;
LAMIVUDINE;
PEGINTERFERON ALPHA2A;
RECOMBINANT ALPHA2B INTERFERON;
TELBIVUDINE;
VIRUS DNA;
ADD ON THERAPY;
CLINICAL TRIAL;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DISEASE COURSE;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG PREFERENCE;
DRUG RESPONSE;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HEPATITIS B;
HEPATITIS B VIRUS;
HIGH RISK POPULATION;
HUMAN;
INCIDENCE;
INFECTION PREVENTION;
INFECTION RISK;
MONOTHERAPY;
NOTE;
PRACTICE GUIDELINE;
PREDICTION;
QUALITY OF LIFE;
REBOUND;
SEROCONVERSION;
TREATMENT DURATION;
UNSPECIFIED SIDE EFFECT;
VIRUS RESISTANCE;
|
|
EID: 40149089559
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2008.14.1.65 Document Type: Note |
|
Times cited : (1)
|
|
References (53)
|
